DUBLIN – Bavarian Nordic A/S picked up a second bulk supply order for its Imvamune smallpox vaccine from the U.S. government, a $100 million deal that comes on top of the $133 million contract it secured last year. It's further evidence that the transition from liquid-frozen formulation to longer-lasting freeze-dried vaccine is under way. Read More
SUZHOU, China – Snapping smartphone pictures of pharmaceutical company slides, entrepreneurs listened intently Thursday in a packed audience attending 15-minute presentations of business development executives looking for innovative products, not only in the Asia-Pacific region, but globally. Read More
SUZHOU, China – At the Chinabio Partnering Forum, a panel of leading Chinese biopharma founders and executives discussed the future of immuno-oncology in China to a packed room in Suzhou, a biotech hub a short distance from Shanghai. The speakers were cautiously optimistic about China's future in this hot new category of cancer treatment, artfully skirting around direct mention of the government's recent ban on immunotherapy following a scandal involving a patient who died after receiving DC-CIK treatment. (See BioWorld Today, May 10, 2016.) Read More
Nuclear DNA from one individual is compatible with mitochondrial DNA from another, and the procedure can be successfully performed with eggs that have been previously frozen. But even very low levels of contamination with donor mitochondrial DNA could cause the resulting stem cells to ultimately revert to having the mitochondrial type the transplant procedure is supposed to prevent, suggesting a need for procedures that can eliminate mitochondrial contamination during nuclear transplant. Read More
The American Civil Liberties Union (ACLU) said Thursday it will proceed with a complaint against Myriad Genetics Inc. for the company's reluctance to fully disclose all genomic data to patients, a predicament that would seem to put the company in violation of a federal guideline on disclosure. Read More
Repligen Corp., of Waltham, Mass. priced an underwritten public offering of $100 million worth of 2.125 percent convertible senior notes due 2021. Read More
Selecta Biosciences Inc., of Watertown, Mass., said it obtained an exclusive license to Anc80, an in silico-designed gene therapy vector, from Massachusetts Eye and Ear for use in a rare disease. Read More
Cesca Therapeutics Inc., of Rancho Cordova, Calif., reported publication, in the International Journal of the Cardiovascular Academy, of data from a pilot study utilizing its technology for treatment of acute myocardial infarction. Read More
